Vyant Bio, Inc. (VYNT)

$0.9221

+0.02 (+2.18%)
Rating:
Recommendation:
-
Symbol VYNT
Price $0.9221
Beta 2.783
Volume Avg. 0.02M
Market Cap 5.450M
Shares () -
52 Week Range 0.8789-9.85
1y Target Est -
DCF Unlevered VYNT DCF ->
DCF Levered VYNT LDCF ->
ROE -205.38% Strong Sell
ROA -187.84% Strong Sell
Operating Margin -
Debt / Equity 66.47% Buy
P/E 0.74 Buy
P/B 0.39 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest VYNT news


Mr. John Roberts
Healthcare
Biotechnology
NASDAQ Capital Market

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.